WQ3.F INNO-GENE SA ZY -10

Basic Materials Biotechnology Frankfurt Exchange
0.5442 EUR
Close of Jan 10, 2026
0.3790 0.3790
Market cap
EUR 18.3M
P/E
19.0x
P/B
3.09x
ROE
-6.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2025.

Is WQ3.F undervalued?

Graham number
Price0.5442
Graham value0.3374
Premium61.3%

WQ3.F trades 61.3% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

INNO-GENE SA ZY -10 fundamental analysis

No fundamental analysis for INNO-GENE SA ZY -10 yet.

INNO-GENE SA ZY -10 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About INNO-GENE SA ZY -10

HyEnergy S.A. provides genetic diagnostic solutions in Poland. The company also develops and implements diagnostic algorithm for prevention and personalization of treatment of solid tumors. In addition, it provides DNA analysis and genetic diseases diagnostic service based on NGS technology. HyEnergy S.A. was formerly known as Inno-Gene S.A. and changed its name to HyEnergy S.A. in October 2024. The company was incorporated in 2010 and is headquartered in Warsaw, Poland.

Full company profile